The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000643370p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
1/05/2026
Date registered
Help: Date registered
27/05/2026
Date last updated
Help: Date last updated
27/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The Impact of Precision Isotretinoin Treatment on rates of Keratinising Desquamative Squamous Metaplasia of the Urinary tract in Adults with a verified pathogenic variant in the RARG gene.
Scientific title
The Impact of Precision Isotretinoin Treatment on rates of Keratinising Desquamative Squamous Metaplasia of the Urinary tract in Adults with a verified pathogenic variant in the RARG gene.
Additional trial identifiers [1] 317171 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Keratinising Desquamative Squamous Metaplasia 341751 0
Condition category
Condition code
Human Genetics and Inherited Disorders 337825 337825 0 0
Other human genetics and inherited disorders
Renal and Urogenital 337925 337925 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Treatment with oral tablet of isotretinoin (starting at 5mg and rising to a maximum of 40mg per day at intervals determined by clinican discretion) over 6-12 months. Doses will be no greater than 0.5mg/kg for any participant. The drug will continue to be escalated monthly up to 6 months unless side effects limit dosing.
Participants will self report compliance by the use of a diary and cross checking this with depletion of the supply of the drug.
Intervention code [1] 333942 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345284 0
Keratinising Desquamative Squamous Metaplasia
Timepoint [1] 345284 0
1 week and then monthly after initiation of treatment for a total period of 6-12 months.
Primary outcome [2] 345285 0
Change in keratinisation of the urothelium as determined by a change in urinary debris excretion and a change in keratinisation of the urothelium as judged by histological staining. These factors will be assessed as a composite outcome.
Timepoint [2] 345285 0
Prior to and 6 months after initiation of treatment
Secondary outcome [1] 461171 0
Change in pain
Timepoint [1] 461171 0
Daily after initiation of treatment for 6-12 months.

Eligibility
Key inclusion criteria
Heterozygous for verified pathogenic variant in the RARG gene as determined by genomic sequencing. The pathogenic variant is p.Arg412*.
Not pregnant
Not on tetracyclines
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Hepatic impairment
Pancreatitis
Pregnancy

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
4 individuals being recruited therefore no power calculation appropriate
Comparison between scores for urinary debris compared to pre-treatment using 2-sided T test

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 28071 0
New Zealand
State/province [1] 28071 0

Funding & Sponsors
Funding source category [1] 321755 0
Charities/Societies/Foundations
Name [1] 321755 0
Curekids
Country [1] 321755 0
New Zealand
Primary sponsor type
University
Name
University of Otago
Address
Country
New Zealand
Secondary sponsor category [1] 324594 0
Charities/Societies/Foundations
Name [1] 324594 0
Curekids
Address [1] 324594 0
Country [1] 324594 0
New Zealand

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320301 0
Southern Health and Disability Ethics Committee
Ethics committee address [1] 320301 0
Ethics committee country [1] 320301 0
New Zealand
Date submitted for ethics approval [1] 320301 0
08/05/2026
Approval date [1] 320301 0
Ethics approval number [1] 320301 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150014 0
Prof Stephen Robertson
Address 150014 0
Department of Paediatrics and Child Health. Faculty of Medicine, University of Otago, 362 Leith Street, Dunedin North, Dunedin 9016
Country 150014 0
New Zealand
Phone 150014 0
+64 212797469
Fax 150014 0
Email 150014 0
Contact person for public queries
Name 150015 0
Stephen Robertson
Address 150015 0
Department of Paediatrics and Child Health. Faculty of Medicine, University of Otago, 362 Leith St., North Dunedin 9016
Country 150015 0
New Zealand
Phone 150015 0
+64 212797469
Fax 150015 0
Email 150015 0
Contact person for scientific queries
Name 150016 0
Stephen Robertson
Address 150016 0
Department of Paediatrics and Child Health. Faculty of Medicine, University of Otago, 362 Leith Street, Dunedin North, Dunedin 9016
Country 150016 0
New Zealand
Phone 150016 0
+64 212797469
Fax 150016 0
Email 150016 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Patient privacy.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.